文献速递胸部肿瘤

阿帕替尼增强EGFR-TKI在EGFR-TKI耐药非小细胞肺癌中的抗肿瘤活性

Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
PubMed 文献 · Eur J Cancer · 2017-08-17

本研究在四株非小细胞肺癌细胞系及H1975获得性耐药移植瘤模型中评估阿帕替尼联合吉非替尼的效应,并回顾性分析16例EGFR-TKI再挑战联合阿帕替尼的患者。联合治疗在体外和体内均增强抗肿瘤作用,患者中位无进展生存期为4.60个月(95%CI 2.23-12.52个月)。

要点

  • 吉非替尼联合阿帕替尼对四株NSCLC细胞系的抑制作用强于单药,H1975最敏感。
  • H1975移植瘤模型中联合治疗较单药延迟肿瘤生长,并更强抑制EGFR、VEGFR2活化及CD31、VEGFA表达。
  • 16例EGFR-TKI再挑战联合阿帕替尼患者的中位无进展生存期为4.60个月(95%CI 2.23-12.52个月)。

核心结论

  • 阿帕替尼在体内和体外均显著增强吉非替尼对T790M相关EGFR-TKI耐药NSCLC的抗肿瘤作用。
  • EGFR-TKI再挑战联合阿帕替尼可能成为T790M或耐药机制不明NSCLC的新选择。

研究设计与样本

  • 体外研究:阿帕替尼、吉非替尼及吉非替尼联合阿帕替尼作用于四株NSCLC细胞系(A549为野生型EGFR,H1975携带L858R和T790M,H1650和HCC827携带E746_A750缺失)。
  • 体内研究:采用注射H1975细胞建立的获得性耐药移植瘤模型。
  • 回顾性评估16例接受EGFR-TKI再挑战联合阿帕替尼的患者。

主要发现

  • 吉非替尼联合阿帕替尼对四株NSCLC细胞系的抑制作用强于吉非替尼单药和阿帕替尼单药,H1975最敏感。
  • 在移植瘤模型中,联合给药较单药延迟肿瘤生长,并更好地抑制EGFR和VEGFR2活化以及CD31(血管生成标志物)和血管内皮生长因子A(肿瘤微环境中重要的促血管生成因子)的表达。
  • 蛋白激酶B/哺乳动物雷帕霉素靶蛋白和细胞外信号调节激酶通路的蛋白表达变化表明联合治疗对促生存信号通路有强效抑制作用。
  • EGFR-TKI再挑战联合阿帕替尼在患者中达到中位无进展生存期4.60个月(95%置信区间2.23-12.52个月)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-rechallenged therapy for EGFR-mutant non-small cell lung cancer (NSCLC) patients who acquired resistance showed moderate efficacy. Considering the high interrelation between EGFR and vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) pathways, we firstly evaluated EGFR-TKI combined with apatinib (a highly selective VEGFR2 inhibitor) in EGFR-TKI-resistant model and patients. METHODS: Effects of apatinib, gefitinib and gefitinib plus apatinib were assessed on four NSCLC cell lines (A549 with wild-type EGFR, H1975 harbouring L858R and T790M, H1650 and HCC827 harbouring E746_A750 deletion) and xenograft model of acquired resistance that was established by injecting H1975 cells. Furthermore, we retrospectively evaluated EGFR-TKI rechallenge with apatinib in 16 patients. RESULTS: Gefitinib plus apatinib strengthened the effect of gefitinib and apatinib alone on the four NSCLC cell lines, and H1975 was the most susceptible one. Co-administration delayed the tumour growth than mono-therapy in the xenograft model and had better effect on inhibiting the activation of EGFR and VEGFR2 and expression of CD31 (an angiogenesis marker) and vascular endothelial growth factor A (an important pro-angiogenesis factor in the tumour microenvironment). Changes in protein expression of protein kinase B/mammalian target of rapamycin and extracellular signal-regulated kinase pathways demonstrated the potent inhibitory effect on the pro-survival signalling pathways by combined therapy. EGFR-TKI rechallenge with apatinib achieved a median progression-free survival of 4.60 months (95% confidence interval, 2.23-12.52 months) in the patients. CONCLUSIONS: Apatinib significantly potentiated the antitumour effect of gefitinib in NSCLC with T790M-related EGFR-TKI resistance both in vivo and vitro. EGFR-TKI rechallenge with apatinib might represent a new option for NSCLC with T790M or unknown resistance mechanism.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Li F, Zhu T, Cao B, et al. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Eur J Cancer. 2017. PMID: 28822888. doi:10.1016/j.ejca.2017.07.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。